Evidence map›Paper›PMID 39961862›Full record

ReviewZeitschrift fur Rheumatologie2025

[Juvenile idiopathic arthritis-Diagnosis and management].

Normi Brück, Christiane Reiser, Prasad Thomas Oommen, Tatjana Welzel

Abstract readReviewEnglish Abstract
PubMed Publisher
In one paragraph

Review in Zeitschrift fur Rheumatologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Normi BrückAbteilung für Pädiatrische Rheumatologie, Klinik und Poliklinik für Kinder- und Jugendmedizin, Medizinische Fakultät und Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Deutschland. normibrueck@ukdd.de.
Christiane ReiserAbteilung für Pädiatrische Rheumatologie und Autoinflammations-Referenzzentrum Tübingen (arcT), Universitätsklinikum Tübingen, Tübingen, Deutschland.
Prasad Thomas OommenKlinik für Kinder-Onkologie, -Hämatologie und Klinische Immunologie, Bereich Pädiatrische Rheumatologie, Medizinische Fakultät der Heinrich-Heine-Universität Düsseldorf, Universitätsklinikum Düsseldorf, Düsseldorf, Deutschland.
Tatjana WelzelPädiatrische Rheumatologie, Universitäts-Kinderspital beider Basel (UKBB), Universität Basel, Basel, Schweiz.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in children and adolescents. Currently, JIA is classified into seven categories according to the International League of Associations for Rheumatology (ILAR) criteria. Diagnosis is primarily clinical and involves excluding age-specific differential diagnoses, which can be particularly challenging in very young children. Early and effective treatment is crucial to minimize disease burden, chronic morbidity and reduced quality of life. Treatment strategies depend on the JIA category and comorbidities. The treatment should follow consensus treatment plans/strategies published by the German initiative Protocols for Classification, Monitoring and Therapy in Pediatric Rheumatology (ProKind) considering the treat-to-target strategy. Since a significant number of patients continue to have symptoms into adulthood, a well-structured transition from pediatric to adult rheumatology care is essential.

Indexed as

Antirheumatic AgentsArthritis, JuvenileRheumatologyAdolescentChildChild, PreschoolDiagnosis, DifferentialEvidence-Based MedicineFemaleGermanyHumansAntirheumatic AgentsArthritis in childhoodDifferential diagnosesTransitionTreatmentUveitis

Identifiers

PMID39961862

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.